Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the European Commission as an add-on treatment to standard-of-care therapies ravulizumab (Ultomiris) or eculizumab (Soliris) for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who suffer from residual haemolytic anaemia. This approval marks a significant advancement for the approximately […]
Alexion, AstraZeneca Rare Disease has agreed to acquire LogicBio Therapeutics, an American clinical-stage genetic medicine company in a deal worth $68 million. As per the terms of the deal, shareholders of the NASDAQ-listed LogicBio Therapeutics will be paid $2.07 per share by Alexion, AstraZeneca Rare Disease. The latter was formed following last year’s $39 billion […]
The UK Competition and Markets Authority (CMA) has launched a phase 1 merger inquiry into $39 billion AstraZeneca’s acquisition of Alexion Pharmaceuticals, a US biopharma company engaged in developing therapies for rare disorders. The British competition regulator will study if the deal announced in December 2020 will lead to a considerable reduction of competition within […]
AstraZeneca has secured its shareholders’ approval for its previously announced $39 billion acquisition of US biopharma company Alexion Pharmaceuticals. The pharma giant expects the acquisition to be completed in the third quarter of this year with the transaction subject to approval from Alexion’s shareholders, certain regulatory approvals, and also other customary closing conditions. Commenting on […]
AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in developing therapies for rare disorders. As per the terms of the deal, Alexion Pharmaceuticals’ shareholders will be paid $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca, valuing […]
Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies for an undisclosed price. The acquisition is said to complement Inozyme’s ongoing development of INZ-701, its lead product candidate which is being investigated for the treatment of ENPP1 and ABCC6 deficiencies, which are both rare diseases of […]
Alexion acquisition of Portola : Alexion Pharmaceuticals has agreed to acquire Portola Pharmaceuticals, a commercial-stage biopharma company focused on life-threatening blood-related disorders, for $1.41 billion. Portola Pharmaceuticals developed Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], which is marketed as Ondexxya in Europe. The drug is the first and only approved Factor Xa inhibitor reversal agent, and […]
Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral sclerosis (ALS). The late-stage clinical trial, which will be held globally by the US pharma company for 50 weeks, will feature nearly 350 adults across a broad patient population. The […]
Ultomiris FDA approval : Alexion Pharmaceuticals has bagged approval from the US Food and Drug Administration (FDA) for Ultomiris (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) in adults and pediatric (one month of age and older) patients. The approval is for the prevention of complement-mediated thrombotic microangiopathy (TMA) in such patient populations. […]
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal as per the latest pharma acquisition news. Achillion is a clinical-stage biopharma company, which is engaged in developing oral small molecule Factor D inhibitors for the treatment of people with […]
